Zydus Cadila has received the final approval from the US Food & Drug Administration (USFDA) to market Methotrexate Tablets USP, 2.5 mg. It is a chemotherapy drug used for leukemias, lymphomas, breast cancer, lung cancer, head and neck cancers and other cancers.
The drug will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 105 approvals and has so far filed nearly 275 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
